Home

Cell Therapeutics (CTIC) Homepage     News     BNews     YMsg     RBMsg     Trials

Contents

  1. PG-TXL
PG-TXL (CT 2103)

  1. 2/23/02 AACR-EORTC-NCI: PG-TXL (CT-2103) Shrinks Tumors in Late-Stage, Previously Unresponsive Cancer PG-TXL was well tolerated and rarely caused serious drug-related side effects. The study results were presented at the 2001 American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-EORTC-NCI) International Conference in Miami. PG-TXL is Cell Therapeutics, Inc.'s (CTI's) investigational anti-cancer product. "The finding that PG-TXL shrinks tumors in patients with advanced cancer who have not responded to other chemotherapies, including Taxol, is exciting because few of these patients typically respond to treatment, and they often experience severe side effects," said Mary G. Bolton, M.D., Ph.D., director, clinical development and project team leader for PG-TXL at CTI. "To date, more than 120 patients have been treated with PG-TXL, and trials are continuing to enroll patients rapidly." Dr. Bolton added that patients on PG-TXL experience very few side effects (e.g., minimal hair loss, infrequent mild neuropathy, minimal nausea). No patient has required dose modification Results have shown that PG-TXL administered in combination with cisplatin shrinks tumors or stops them from progressing in patients with advanced solid tumors. Of the seven patients, three have experienced a partial response (two patients with recurrent ovarian cancer and one patient with recurrent peritoneal cancer) and three have experienced stable disease (one patient each with recurrent endometrial cancer, thyroid cancer and advanced peritoneal cancer). Adverse events were mild to moderate; one patient elected to discontinue chemotherapy after six cycles and a partial response.

  2. 2/23/02 Press Releases and Background Information

  3. 2/23/02 Background on TAXOL

Home